KALA Share Price | KALA BIO, Inc. Stock Analysis & Recommendation

Q: What does KALA BIO, Inc. do?

Overview:KALA BIO, Inc. is a biopharmaceutical company focused on developing and commercializing therapeutics using its nanoparticle-based Mucus Penetrating Particles technology, primarily targeting eye diseases. It operates within the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.Financial Snapshot:Most recent Net Profit: -9 Million (Quarterly Results - Mar 2025)Market cap: USD 26.97 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making)Industry P/E: NADividend Yield: 0.00%Debt Equity: -1.96Return on Equity: -617.36%Price to Book: 4.73Contact Details:Address: 490 ARSENAL WAY, SUITE 120, WATERTOWN MA: 02472Tel: ['1 781 9965252', '1 212 3621200']Fax: 1 781 6420399Website: http://kalarx.com/

Q: Who are in the management team of KALA BIO, Inc.?

As of March 2022, the management team of KALA BIO, Inc. includes Mr. Mark Iwicki, who serves as the Chairman of the Board, President, and Chief Executive Officer. Additionally, the board features Mr. Andrew Koven as the Lead Independent Director, along with independent directors Dr. Gregory Grunberg, Mr. Robert Paull, Mr. Gregory Perry, and Mr. Howard Rosen.

Q: Is KALA BIO, Inc. overvalued or undervalued?

As of 4 August 2023, KALA BIO, Inc. has moved from a valuation grade of risky to does not qualify, indicating a significant deterioration in its investment appeal. The company is currently overvalued, as evidenced by its Price to Book Value of 4.68, a negative EV to EBITDA of -0.40, and an alarming ROE of -617.36%. These figures suggest that the company is struggling financially and is not generating positive returns for its shareholders.In comparison to its peers, KALA BIO, Inc. has a less favorable position, with Regulus Therapeutics, Inc. showing a P/E ratio of -11.9462 and an EV to EBITDA of -9.7830, while Cumberland Pharmaceuticals, Inc. is rated risky with a P/E of -21.9132. The stark differences in these ratios highlight KALA's relative weakness in the market. Furthermore, KALA BIO's stock has significantly underperformed against the S&P 500, with a year-to-date return of -42.07% compared to the index's 2.44%.

Q: Is KALA BIO, Inc. technically bullish or bearish?

As of 20 August 2025, the technical trend for KALA BIO, Inc. has changed from mildly bullish to bullish. The current technical stance is bullish with strong indicators supporting this view, particularly in the daily moving averages and the weekly KST and OBV, both of which are bullish. However, the weekly and monthly RSI readings are bearish, suggesting some caution. The Bollinger Bands indicate a bullish stance on the monthly timeframe. In terms of performance, KALA BIO has significantly outperformed the S&P 500 across multiple periods, with a 1-month return of 104.37% compared to the S&P 500's 2.33%, and a 1-year return of 202.33% versus 17.14%. Overall, the strength of the bullish trend is supported by the recent price action and strong returns relative to the benchmark.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

1.45 M

Shareholding (Dec 2025)

FII

0.23%

Held by 13 FIIs

DII

95.56%

Held by 2 DIIs

Promoter

2.73%

How big is KALA BIO, Inc.?

22-Jun-2025

As of Jun 18, KALA BIO, Inc. has a market capitalization of 26.97 million and reported net sales of 0.00 million with a net profit of -35.66 million over the last four quarters. Shareholder's funds are 12.33 million, and total assets amount to 55.48 million.

View full answer

What does KALA BIO, Inc. do?

22-Jun-2025

KALA BIO, Inc. is a biopharmaceutical company specializing in developing therapeutics for eye diseases using its nanoparticle-based technology. It has a market cap of approximately $26.97 million and reported a net profit loss of $9 million as of March 2025.

View full answer

Who are in the management team of KALA BIO, Inc.?

22-Jun-2025

As of March 2022, KALA BIO, Inc.'s management team includes Mr. Mark Iwicki as Chairman, President, and CEO, with Mr. Andrew Koven as Lead Independent Director and independent directors Dr. Gregory Grunberg, Mr. Robert Paull, Mr. Gregory Perry, and Mr. Howard Rosen.

View full answer

Is KALA BIO, Inc. overvalued or undervalued?

25-Jun-2025

As of August 4, 2023, KALA BIO, Inc. is considered overvalued and has deteriorated to a "does not qualify" rating due to poor financial metrics, including a Price to Book Value of 4.68 and a ROE of -617.36%, significantly underperforming its peers and the S&P 500.

View full answer

Is KALA BIO, Inc. technically bullish or bearish?

20-Sep-2025

As of August 20, 2025, KALA BIO, Inc. shows a bullish technical trend with strong indicators, despite some bearish RSI readings, and has significantly outperformed the S&P 500 with a 1-month return of 104.37% and a 1-year return of 202.33%.

View full answer

Compare KALA BIO, Inc. with Similar Stocks

Indaptus Therapeutics, Inc.NRX Pharmaceuticals, Inc.NLS Pharmaceutics Ltd.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 243 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.89

Return on Equity

451.11%

Price to Book

-28.02

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

1 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-81.98%

6 Months

-88.89%

1 Year

-97.69%

2 Years

-98.88%

3 Years

-99.5%

4 Years

-99.8%

5 Years

-99.97%

KALA BIO, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-100.00%

EBIT Growth (5y)

8.79%

EBIT to Interest (avg)

-10.09

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.96

Sales to Capital Employed (avg)

0.01

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

65.72%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-28.02

EV to EBIT

-6.02

EV to EBITDA

-6.06

EV to Capital Employed

-250.51

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

Negative BV

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

Mildly Bullish

Bearish

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Strategic Entities

Domestic Funds

Held in 3 Schemes (1.48%)

Foreign Institutions

Held by 13 Foreign Institutions (0.23%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Sep 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 109.21% vs 32.14% in Sep 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-10.20",
          "val2": "-10.50",
          "chgp": "2.86%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "1.00",
          "chgp": "-90.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "5.80",
          "val2": "3.40",
          "chgp": "70.59%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "0.70",
          "val2": "-7.60",
          "chgp": "109.21%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 29.87% vs 8.77% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-42.10",
          "val2": "-40.20",
          "chgp": "-4.73%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "3.30",
          "val2": "5.80",
          "chgp": "-43.10%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "9.00",
          "val2": "-0.50",
          "chgp": "1,900.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-27.00",
          "val2": "-38.50",
          "chgp": "29.87%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-10.20

-10.50

2.86%

Interest

0.10

1.00

-90.00%

Exceptional Items

5.80

3.40

70.59%

Consolidate Net Profit

0.70

-7.60

109.21%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Sep 2025

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is 109.21% vs 32.14% in Sep 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-42.10

-40.20

-4.73%

Interest

3.30

5.80

-43.10%

Exceptional Items

9.00

-0.50

1,900.00%

Consolidate Net Profit

-27.00

-38.50

29.87%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 29.87% vs 8.77% in Dec 2024

All Annual Results

Company CV

About KALA BIO, Inc.

KALA BIO, Inc.

Pharmaceuticals & Biotechnology

Kala Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles, or MPP, technology. The Company’s initial focus is on the treatment of eye diseases. The Company’s product candidate includes KPI-121 1%, KPI-121 0.25% and MPP rTKI Program. The Company has completed two Phase III clinical trials for KPI-121 1% . The KPI-121 0.25% is the Company’s product candidate for temporary relief of signs and symptoms of dry eye disease. KPI-121 1% is the twice-a-day product candidate for treatment of post-operative inflammation and pain following ocular surgery. MPP rTKI Program is therapies for retinal diseases that should be injected directly into the patient's eye, often at monthly intervals.

Company Coordinates

Company Details

490 ARSENAL WAY, SUITE 120 , WATERTOWN MA : 02472

Tel: 1 781 99652521 212 3621200

http://kalarx.com/

Registrar Details